Possible role of propofol's cyclooxygenase-inhibiting property in alleviating dopaminergic neuronal loss in the substantia nigra in an MPTP-induced murine model of Parkinson's disease

Brain Research

Volumn 1387, Issue , 2011, Pages 125-133

  Kubo, Kozue ^a   Inada, Takefumi ^a,b   Shingu, Koh ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Cyclooxygenase 2; Microglia; Parkinson's disease; Propofol

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ARACHIDONIC ACID; INTERLEUKIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROPOFOL; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SUBSTANTIA NIGRA;

ANIMALS; BLOTTING, WESTERN; CELL SEPARATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; MPTP POISONING; NEURONS; NEUROPROTECTIVE AGENTS; PROPOFOL; SUBSTANTIA NIGRA;

MURINAE; MUS;

EID: 79954418961     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.02.079     Document Type: Article

References (48)

1. J. Ahrens, G. Haeseler, M. Leuwer, B. Mohammadi, K. Krampfl, R. Dengler, and J. Bufler 2,6 Di-tert-butylphenol, a nonanesthetic propofol analog, modulates alpha1beta glycine receptor function in a manner distinct from propofol Anesth. Analg. 99 2004 91 96 (Pubitemid 38808171)
2. D. Bai, P.S. Pennefather, J.F. MacDonald, and B.A. Orser The general anesthetic propofol slows deactivation and desensitization of GABA(A) receptors J. Neurosci. 19 1999 10635 10646 (Pubitemid 30235710)
3. R.B. Banati, S.E. Daniel, and S.B. Blunt Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease Mov. Disord. 13 1998 221 227 (Pubitemid 28127795)
4. N.G. Bazan COX-2 as a multifunctional neuronal modulator Nat. Med. 7 2001 414 415 (Pubitemid 32298540)
5. N.G. Bazan, V. Colangelo, and W.J. Lukiw Prostaglandins and other lipid mediators in Alzheimer's disease Prostaglandins Other Lipid Mediat. 68-69 2002 197 210 (Pubitemid 35247397)
6. R. Bianchi, I. Giambanco, and R. Donato S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha Neurobiol. Aging 31 2010 665 677
7. D.M. Bronstein, I. Perez-Otano, V. Sun, S.B. Mullis Sawin, J. Chan, G.C. Wu, P.M. Hudson, L.Y. Kong, J.S. Hong, and M.K. McMillian Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures Brain Res. 704 1995 112 116
8. R. Brookmeyer, S. Gray, and C. Kawas Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset Am. J. Public Health 88 1998 1337 1342 (Pubitemid 28402270)
9. H. Chen, S.M. Zhang, M.A. Hernan, M.A. Schwarzschild, W.C. Willett, G.A. Colditz, F.E. Speizer, and A. Ascherio Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease Arch. Neurol. 60 2003 1059 1064 (Pubitemid 36975791)
10. G. Cheung, O. Kann, S. Kohsaka, K. Fǎerber, and H. Kettenmann GABAergic activities enhance macrophage inflammatory protein-1alpha release from microglia (brain macrophages) in postnatal mouse brain J. Physiol. 587 2009 753 768
11. L.M. de Lau, P.C. Giesbergen, M.C. de Rijk, A. Hofman, P.J. Koudstaal, and M.M. Breteler Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study Neurology 63 2004 1240 1244 (Pubitemid 39350024)
12. M. Djukic, A. Mildner, H. Schmidt, D. Czesnik, W. Brück, J. Priller, R. Nau, and M. Prinz Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice Brain 129 2006 2394 2403 (Pubitemid 44522124)
13. E. Esposito, V. Di Matteo, A. Benigno, M. Pierucci, G. Crescimanno, and G. Di Giovanni Non-steroidal anti-inflammatory drugs in Parkinson's disease Exp. Neurol. 205 2007 295 312 (Pubitemid 46778915)
14. M. Etminan, S. Gill, and A. Samii Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies BMJ 327 2003 128
15. F. Gonzalez-Scarano, and G. Baltuch Microglia as mediators of inflammatory and degenerative diseases Annu. Rev. Neurosci. 22 1999 219 240 (Pubitemid 29144887)
16. E. Hasegawa, K. Takeshige, T. Oishi, Y. Murai, and S. Minakami 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles Biochem. Biophys. Res. Commun. 170 1990 1049 1055 (Pubitemid 20273373)
17. S. Hunot, M. Vila, P. Teismann, R. Davis, E. Hirsch, S. Przedborski, P. Rakic, and R. Flavell JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease Proc. Natl Acad. Sci. USA 101 2004 665 670 (Pubitemid 38084694)
18. T. Inada, K. Kubo, T. Kambara, and K. Shingu Propofol inhibits cyclo-oxygenase activity in human monocytic THP-1 cells Can. J. Anaesth. 56 2009 222 229
19. Q. Jiang, I. Elson-Schwab, C. Courtemanche, and B.N. Ames gamma-Tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells Proc. Natl Acad. Sci. USA 97 2000 11494 11499
20. T. Kambara, T. Inada, K. Kubo, and K. Shingu Propofol suppresses prostaglandin E(2) production in human peripheral monocytes Immunopharmacol. Immunotoxicol. 31 2009 117 126
21. H. Kato, R. Kurosaki, C. Oki, and T. Araki Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice Brain Res. 1030 2004 66 73 (Pubitemid 39563827)
22. T. Kawasaki, K. Ishihara, Y. Ago, A. Baba, and T. Matsuda Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum J. Pharmacol. Exp. Ther. 322 2007 274 281 (Pubitemid 46956378)
23. L. Landino, B. Crews, M. Timmons, J. Morrow, and L. Marnett Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis Proc. Natl Acad. Sci. USA 93 1996 15069 15074 (Pubitemid 27009553)
24. M. Lee, C. Schwab, and P.L. McGeer Astrocytes are GABAergic cells that modulate microglial activity Glia 59 2011 152 165
25. M. Lin, and M. Beal Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases Nature 443 2006 787 795 (Pubitemid 44622683)
26. B. Liu, H.M. Gao, J.Y. Wang, G.H. Jeohn, C.L. Cooper, and J.S. Hong Role of nitric oxide in inflammation-mediated neurodegeneration Ann. NY Acad. Sci. 962 2002 318 331 (Pubitemid 34592321)
27. J.L. Madrigal, B. Garcia-Bueno, M.A. Moro, I. Lizasoain, P. Lorenzo, and J.C. Leza Relationship between cyclooxygenase-2 and nitric oxide synthase-2 in rat cortex after stress Eur. J. Neurosci. 18 2003 1701 1705 (Pubitemid 37215122)
28. C. Malagelada, Z. Jin, V. Jackson-Lewis, S. Przedborski, and L. Greene Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease J. Neurosci. 30 2010 1166 1175
29. J.E. Merrill, Y. Koyanagi, J. Zack, L. Thomas, F. Martin, and I.S. Chen Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1 J. Virol. 66 1992 2217 2225
30. L. Minghetti, E. Polazzi, A. Nicolini, and G. Levi Opposite regulation of prostaglandin E2 synthesis by transforming growth factor-beta1 and interleukin 10 in activated microglial cultures J. Neuroimmunol. 82 1998 31 39 (Pubitemid 28129333)
31. Y. Nakamura Regulating factors for microglial activation Biol. Pharm. Bull. 25 2002 945 953 (Pubitemid 39663211)
32. D. Nikolic, and R.B. van Breemen DNA oxidation induced by cyclooxygenase-2 Chem. Res. Toxicol. 14 2001 351 354 (Pubitemid 32367467)
33. A. Nimmerjahn, F. Kirchhoff, and F. Helmchen Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo Science 308 2005 1314 1318 (Pubitemid 40746128)
34. C. Olanow The scientific basis for the current treatment of Parkinson's disease Annu. Rev. Med. 55 2004 41 60 (Pubitemid 38316715)
35. J. Phillis, L. Horrocks, and A. Farooqui Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders Brain Res. Rev. 52 2006 201 243 (Pubitemid 44291802)
36. E. Polazzi, and A. Contestabile Reciprocal interactions between microglia and neurons: from survival to neuropathology Rev. Neurosci. 13 2002 221 242 (Pubitemid 35178154)
37. S. Przedborski, V. Jackson-Lewis, R. Djaldetti, G. Liberatore, M. Vila, S. Vukosavic, and G. Almer The parkinsonian toxin MPTP: action and mechanism Restor. Neurol. Neurosci. 16 2000 135 142 (Pubitemid 30159159)
38. M. Schiess Nonsteroidal anti-inflammatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away? Arch. Neurol. 60 2003 1043 1044 (Pubitemid 36975788)
39. W. Streit Microglia as neuroprotective, immunocompetent cells of the CNS Glia 40 2002 133 139 (Pubitemid 35337371)
40. A. Suzumura, S. Mezitis, N. Gonatas, and D. Silberberg MHC antigen expression on bulk isolated macrophage-microglia from newborn mouse brain: induction of Ia antigen expression by gamma-interferon J. Neuroimmunol. 15 1987 263 278 (Pubitemid 17108036)
41. P. Teismann, and B. Ferger Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease Synapse 39 2001 167 174 (Pubitemid 32104022)
42. P. Teismann, K. Tieu, D. Choi, D. Wu, A. Naini, S. Hunot, M. Vila, V. Jackson-Lewis, and S. Przedborski Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration Proc. Natl Acad. Sci. USA 100 2003 5473 5478 (Pubitemid 36542729)
43. S.F. Tzeng, H.Y. Hsiao, and O.T. Mak Prostaglandins and cyclooxygenases in glial cells during brain inflammation Curr. Drug Targets Inflamm. Allergy 4 2005 335 340
44. C. Vanlersberghe, and F. Camu Propofol Handb. Exp. Pharmacol. 2008 227 252
45. R. Vijitruth, M. Liu, D. Choi, X. Nguyen, R. Hunter, and G. Bing Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease J. Neuroinflammation 3 2006 6
46. T. Wang, Z. Pei, W. Zhang, B. Liu, R. Langenbach, C. Lee, B. Wilson, J. Reece, D. Miller, and J. Hong MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration FASEB J. 19 2005 1134 1136 (Pubitemid 40946442)
47. Y. Wang, Y. Zhang, Z. Wei, H. Li, H. Zhou, and Z. Zhang JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease J. Neurol. Sci. 285 2009 172 177
48. Z. Xiang, L. Ho, J. Valdellon, D. Borchelt, K. Kelley, L. Spielman, P.S. Aisen, and G.M. Pasinetti Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology Neurobiol. Aging 23 2002 327 334 (Pubitemid 34312015)